公开(公告)号：US20150018747A1

公开(公告)日：2015-01-15

申请号：US14311082

申请日：2014-06-20

Applicant: Abbott Cardiovascular Systems Inc.

Inventor： Eugene T. Michal ,  Jeffrey Ross

IPC: A61N1/362 ,  A61L27/54 ,  A61L27/50 ,  A61N1/365 ,  A61L27/20

CPC classification number: A61N1/3625 ,  A61K9/0024 ,  A61K31/00 ,  A61K31/728 ,  A61K31/732 ,  A61K31/734 ,  A61K31/78 ,  A61K31/79 ,  A61K36/886 ,  A61K38/40 ,  A61K41/0042 ,  A61K45/06 ,  A61K47/02 ,  A61K47/34 ,  A61K47/60 ,  A61K47/62 ,  A61K49/0404 ,  A61L24/043 ,  A61L27/20 ,  A61L27/50 ,  A61L27/54 ,  A61L2430/20 ,  A61N1/36521 ,  A61K2300/00

Abstract: Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle using a combination of therapies. The method may include the introduction of structurally reinforcing agents. In other embodiments, agents may be introduced into a ventricle to increase compliance of the ventricle. The prevention of remodeling may include the prevention of thinning of the ventricular infarct zone. Another embodiment includes the reversing or prevention of ventricular remodeling with electro-stimulatory therapy. The unloading of the stressed myocardium over time effects reversal of undesirable ventricular remodeling. These therapies may be combined with structurally reinforcing therapies. In other embodiments, the structurally reinforcing component may be accompanied by other therapeutic agents. These agents may include but are not limited to pro-fibroblastic and angiogenic agents.

Abstract translation: 用于治疗心肌梗塞的方法，装置，试剂盒和组合物。 在一个实施方案中，该方法包括使用疗法的组合来防止心室梗死区的重塑。 该方法可以包括引入结构上增强剂。 在其它实施方案中，可将药剂引入心室以增加心室的依从性。 预防重塑可能包括防止心室梗死区变薄。 另一个实施方案包括用电刺激治疗逆转或预防心室重构。 随着时间的推移，应力心肌的卸载会影响不良心室重构的逆转。 这些治疗方法可能与结构加强疗法相结合。 在其它实施方案中，结构上增强组分可以伴随其它治疗剂。 这些药剂可以包括但不限于前成纤维细胞和血管生成剂。

公开(公告)号：US09775930B2

公开(公告)日：2017-10-03

申请号：US14685474

申请日：2015-04-13

Applicant: Abbott Cardiovascular Systems Inc. ,  Medical University of South Carolina

Inventor： Eugene T. Michal ,  Shubhayu Basu ,  Alexander J. Sheehy ,  Francis G. Spinale ,  Rupak Mukherjee

IPC: C12P7/28 ,  A61L27/26 ,  A61L27/20 ,  A61L27/22 ,  A61L27/50 ,  A61L27/52 ,  A61L27/38

CPC classification number: A61L27/26 ,  A61L27/20 ,  A61L27/22 ,  A61L27/3834 ,  A61L27/50 ,  A61L27/52 ,  A61L2300/418 ,  A61L2300/64 ,  A61L2400/06 ,  A61L2430/20 ,  C08L5/04 ,  C08L89/00

Abstract: A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture.

公开(公告)号：US20170258961A9

公开(公告)日：2017-09-14

申请号：US14685474

申请日：2015-04-13

Applicant: Abbott Cardiovascular Systems Inc. ,  Medical University of South Carolina

Inventor： Eugene T. Michal ,  Shubhayu Basu ,  Alexander J. Sheehy ,  Francis G. Spinale ,  Rupak Mukherjee

IPC: A61L27/26 ,  A61L27/38

CPC classification number: A61L27/26 ,  A61L27/20 ,  A61L27/22 ,  A61L27/3834 ,  A61L27/50 ,  A61L27/52 ,  A61L2300/418 ,  A61L2300/64 ,  A61L2400/06 ,  A61L2430/20 ,  C08L5/04 ,  C08L89/00

Abstract: A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture.

公开(公告)号：US09084671B2

公开(公告)日：2015-07-21

申请号：US13942474

申请日：2013-07-15

Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC.

Inventor： Eugene T. Michal ,  Ashok A. Shah ,  Ni Ding

IPC: A61F2/06 ,  A61L31/10 ,  A61L31/16

CPC classification number: A61F2/06 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/25 ,  A61L2300/252 ,  A61L2300/45

Abstract: A coating for an implantable device such as a stent is provided including micronized peptides. A method of making the same is also provided.

Abstract translation: 提供了用于诸如支架的可植入装置的涂层，其包括微粉化肽。 还提供了制造该方法的方法。

公开(公告)号：US20150011502A1

公开(公告)日：2015-01-08

申请号：US14491652

申请日：2014-09-19

Applicant: Abbott Cardiovascular Systems Inc.

Inventor： John Stankus ,  Eugene T. Michal

IPC: A61K47/02 ,  A61K31/732 ,  A61K31/734

CPC classification number: A61N1/3625 ,  A61K9/0024 ,  A61K31/00 ,  A61K31/728 ,  A61K31/732 ,  A61K31/734 ,  A61K31/78 ,  A61K31/79 ,  A61K36/886 ,  A61K38/40 ,  A61K41/0042 ,  A61K45/06 ,  A61K47/02 ,  A61K47/34 ,  A61K47/60 ,  A61K47/62 ,  A61K49/0404 ,  A61L24/043 ,  A61L27/20 ,  A61L27/50 ,  A61L27/54 ,  A61L2430/20 ,  A61N1/36521 ,  A61K2300/00

Abstract: Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle. In other embodiments, the method includes the introduction of structural reinforcing agents such as those agents containing aloe-derived pectin. In other embodiments, the structural reinforcing agent may be accompanied by other therapeutic agents. These agents may include, but are not, limited to pro-fibroblastic and angiogenic agents.

Abstract translation: 用于治疗心肌梗塞的方法，装置，试剂盒和组合物。 在一个实施例中，该方法包括防止脑室梗死区的重塑。 在其它实施方案中，该方法包括引入结构增强剂，例如含有芦荟衍生果胶的那些试剂。 在其它实施方案中，结构增强剂可以伴随其他治疗剂。 这些试剂可以包括但不限于前成纤维细胞和血管生成剂。

公开(公告)号：US20140017200A1

公开(公告)日：2014-01-16

申请号：US13941759

申请日：2013-07-15

Applicant: Abbott Cardiovascular Systems Inc.

Inventor： Eugene T. Michal ,  Olof Mikael Trollsas ,  Shubhayu Basu

IPC: A61K47/34

CPC classification number: A61K47/34 ,  A61K9/0024 ,  A61K9/06 ,  A61K35/12 ,  A61K38/00 ,  A61L27/26 ,  A61L27/38 ,  A61L27/50 ,  A61K2300/00

Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.

Abstract translation: 本文公开了组合物，制造方法和心肌梗死后治疗方法。 在一些实施方案中，组合物包含至少两种组分。 在一个实施方案中，第一组分可以包括第一官能化聚合物和具有至少一个细胞粘附位点的物质，其在约6.5的pH下在第一缓冲液中组合。 第二组分可以包括pH在约7.5和9.0之间的第二缓冲液。 第二官能化聚合物可以包括在第一或第二组分中。 在一些实施方案中，组合物可以包括至少一种细胞类型和/或至少一种生长因子。 在一些实施方案中，本发明的组合物可以通过双孔注射装置递送至治疗区域，例如心肌梗死后区域。